Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 6
Submit an article Journal homepage
191
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

Rebecca B. KlisovicDivision of Hematology, Department of Medicine
,
William BlumDivision of Hematology, Department of Medicine;The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Zhongfa LiuDivision of Pharmaceutics, College of Pharmacy
,
Zhiliang XieDivision of Pharmaceutics, College of Pharmacy
,
Cheryl KefauverThe Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Lenguyen HuynhDivision of Hematology, Department of Medicine
,
James A. ZwiebelNational Cancer Institute, Bethesda, MD, USA
,
Steven M. DevineDivision of Hematology, Department of Medicine;The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
John C. ByrdDivision of Hematology, Department of Medicine;The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Michael R. GreverDivision of Hematology, Department of Medicine;The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Kenneth K. ChanDivision of Pharmaceutics, College of Pharmacy;The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
&
Guido MarcucciDivision of Hematology, Department of Medicine;The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USACorrespondence[email protected]
 show all
Pages 1332-1336 | Received 22 May 2013, Accepted 23 Aug 2013, Published online: 01 Nov 2013
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

We hypothesized that GTI-2040, a 20-mer oligonucleotide complementary to the R2 subunit mRNA of ribonucleotide reductase, combined with high dose cytarabine (HiDAC) would result in enhanced cytotoxicity by favoring Ara-CTP DNA incorporation. In a phase I dose escalation trial, adults (≥ 60 years) with refractory or relapsed acute myeloid leukemia (AML) received daily HiDAC plus infusional GTI-2040. Using a novel assay, evidence of intracellular drug accumulation and target R2 down-regulation was observed. GTI-2040/HiDAC can be administered safely. However, with no complete remissions observed, alternative doses and schedules may need to be investigated to achieve clinical activity in older patients with AML.

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

This study was supported by NCI U01 CA 076576-10 and NCI R21 CA 105879.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.